Head, Laboratory of Biotechnology and Radiobiology, Sharett Institute of Oncology, Hadassah Medical Center.
Affiliated to the Hebrew University Medical School, Jerusalem

His multi-focus research group investigates tissue regeneration and adult stem cell isolation, expansion and implantation and related fibrin based technologies as well as other aspect of cell therapy. He has also conducted research in radiobiology and cancer research. His earlier projects included a participation in the development at Hadassah and the Hebrew University of the DXS for non-invasive analysis of trace element in external tissues and erecting the device for a wide range of clinical applications. Besides his major academic activities since then he was the Co-Founder and Chief Scientist of Hapto-Biotech Israel, LTD, the first startup company of Hadasit, Hadassah's technology transfer company, which later merged with Forticell Biosciences of New York. He also developed biotechnology project for Metamorfix Israel. His recent research was associated with the development of new breakthrough cell therapy approach for treating acute radiation syndrome and bone marrow failure with Pluristem Therapeutics, Israel.

Prof. Gorodetsky had his post doctoral research program in clinical radiobiology and had a research position in Radiobiological Sciences at UCLA Medical Center between 1985-1988. He received a Ph.D. in experimental medicine and cancer Research on 1985 and had his BSc in Biology and MSc in Biphysics and Neurobiology at the Hebrew University, Jerusalem.

Raphael Gorodetsky has 100 peer reviewed scientific publications. He also wrote and edited in 2011 the .book "Stem Cell-Based Tissue Repair", a comprehensive compendium of the views of leading researchers in this rapidly advancing field of research, published in Cambridge, GB, by the Royal Society of Chemistry.
He was an invited speaker or chair in more than 25 international conferences in the recent 10 years and is also currently the Secretary of the Israeli stem cells Society.